Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands.
Identifieur interne : 000118 ( Canada/Analysis ); précédent : 000117; suivant : 000119Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands.
Auteurs : Sheila Riazi [Canada] ; Marilyn Green Larach ; Charles Hu ; Duminda Wijeysundera ; Christine Massey ; Natalia KraevaSource :
- Anesthesia and analgesia [ 1526-7598 ] ; 2014.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Anesthésiques (effets indésirables), Caféine (effets indésirables), Canada, Canal de libération du calcium du récepteur à la ryanodine (génétique), Dantrolène (effets indésirables), Dantrolène (usage thérapeutique), Enfant, Enfant d'âge préscolaire, Enregistrements, Femelle, Fièvre (diagnostic), Halothane (effets indésirables), Humains, Hypercapnie (diagnostic), Hyperthermie maligne (épidémiologie), Hyperthermie maligne (étiologie), Incidence, Jeune adulte, Mutation, Mâle, Nourrisson, Sujet âgé, Suxaméthonium (), Tachycardie (diagnostic), Études rétrospectives.
- MESH :
- diagnostic : Fièvre, Hypercapnie, Tachycardie.
- effets indésirables : Anesthésiques, Caféine, Dantrolène, Halothane.
- génétique : Canal de libération du calcium du récepteur à la ryanodine.
- usage thérapeutique : Dantrolène.
- épidémiologie : Hyperthermie maligne.
- étiologie : Hyperthermie maligne.
- Adolescent, Adulte, Adulte d'âge moyen, Canada, Enfant, Enfant d'âge préscolaire, Enregistrements, Femelle, Humains, Incidence, Jeune adulte, Mutation, Mâle, Nourrisson, Sujet âgé, Suxaméthonium, Études rétrospectives.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Anesthetics (adverse effects), Caffeine (adverse effects), Canada, Child, Child, Preschool, Dantrolene (adverse effects), Dantrolene (therapeutic use), Female, Fever (diagnosis), Halothane (adverse effects), Humans, Hypercapnia (diagnosis), Incidence, Infant, Male, Malignant Hyperthermia (epidemiology), Malignant Hyperthermia (etiology), Middle Aged, Mutation, Registries, Retrospective Studies, Ryanodine Receptor Calcium Release Channel (genetics), Succinylcholine (chemistry), Tachycardia (diagnosis), Young Adult.
- MESH :
- chemical , adverse effects : Anesthetics, Caffeine, Dantrolene, Halothane.
- chemical , chemistry : Succinylcholine.
- chemical , genetics : Ryanodine Receptor Calcium Release Channel.
- chemical , therapeutic use : Dantrolene.
- geographic : Canada.
- diagnosis : Fever, Hypercapnia, Tachycardia.
- epidemiology : Malignant Hyperthermia.
- etiology : Malignant Hyperthermia.
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Incidence, Infant, Male, Middle Aged, Mutation, Registries, Retrospective Studies, Young Adult.
Abstract
Between 1992 and 2011, 373 Canadian individuals with adverse anesthetic reaction were referred to the Malignant Hyperthermia Unit in Toronto, Ontario, Canada for malignant hyperthermia (MH) diagnostic testing. We analyzed the epidemiologic characteristics of the index adverse anesthetics for those probands who were confirmed to be MH susceptible.
DOI: 10.1213/ANE.0b013e3182937d8b
PubMed: 23842196
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003D93
- to stream PubMed, to step Curation: 003D66
- to stream PubMed, to step Checkpoint: 003D66
- to stream Ncbi, to step Merge: 000165
- to stream Ncbi, to step Curation: 000165
- to stream Ncbi, to step Checkpoint: 000165
- to stream Main, to step Merge: 002392
- to stream Main, to step Curation: 002296
- to stream Main, to step Exploration: 002296
- to stream Canada, to step Extraction: 000118
Links to Exploration step
pubmed:23842196Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands.</title><author><name sortKey="Riazi, Sheila" sort="Riazi, Sheila" uniqKey="Riazi S" first="Sheila" last="Riazi">Sheila Riazi</name><affiliation wicri:level="1"><nlm:affiliation>From the *Malignant Hyperthermia Investigation Unit, Toronto General Hospital, University Health Network; †Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada; ‡The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States, Pittsburgh, Pennsylvania; and §Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>From the *Malignant Hyperthermia Investigation Unit, Toronto General Hospital, University Health Network; †Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada; ‡The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States, Pittsburgh, Pennsylvania; and §Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Larach, Marilyn Green" sort="Larach, Marilyn Green" uniqKey="Larach M" first="Marilyn Green" last="Larach">Marilyn Green Larach</name></author><author><name sortKey="Hu, Charles" sort="Hu, Charles" uniqKey="Hu C" first="Charles" last="Hu">Charles Hu</name></author><author><name sortKey="Wijeysundera, Duminda" sort="Wijeysundera, Duminda" uniqKey="Wijeysundera D" first="Duminda" last="Wijeysundera">Duminda Wijeysundera</name></author><author><name sortKey="Massey, Christine" sort="Massey, Christine" uniqKey="Massey C" first="Christine" last="Massey">Christine Massey</name></author><author><name sortKey="Kraeva, Natalia" sort="Kraeva, Natalia" uniqKey="Kraeva N" first="Natalia" last="Kraeva">Natalia Kraeva</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:23842196</idno><idno type="pmid">23842196</idno><idno type="doi">10.1213/ANE.0b013e3182937d8b</idno><idno type="wicri:Area/PubMed/Corpus">003D93</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003D93</idno><idno type="wicri:Area/PubMed/Curation">003D66</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003D66</idno><idno type="wicri:Area/PubMed/Checkpoint">003D66</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003D66</idno><idno type="wicri:Area/Ncbi/Merge">000165</idno><idno type="wicri:Area/Ncbi/Curation">000165</idno><idno type="wicri:Area/Ncbi/Checkpoint">000165</idno><idno type="wicri:Area/Main/Merge">002392</idno><idno type="wicri:Area/Main/Curation">002296</idno><idno type="wicri:Area/Main/Exploration">002296</idno><idno type="wicri:Area/Canada/Extraction">000118</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands.</title><author><name sortKey="Riazi, Sheila" sort="Riazi, Sheila" uniqKey="Riazi S" first="Sheila" last="Riazi">Sheila Riazi</name><affiliation wicri:level="1"><nlm:affiliation>From the *Malignant Hyperthermia Investigation Unit, Toronto General Hospital, University Health Network; †Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada; ‡The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States, Pittsburgh, Pennsylvania; and §Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>From the *Malignant Hyperthermia Investigation Unit, Toronto General Hospital, University Health Network; †Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada; ‡The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States, Pittsburgh, Pennsylvania; and §Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Larach, Marilyn Green" sort="Larach, Marilyn Green" uniqKey="Larach M" first="Marilyn Green" last="Larach">Marilyn Green Larach</name></author><author><name sortKey="Hu, Charles" sort="Hu, Charles" uniqKey="Hu C" first="Charles" last="Hu">Charles Hu</name></author><author><name sortKey="Wijeysundera, Duminda" sort="Wijeysundera, Duminda" uniqKey="Wijeysundera D" first="Duminda" last="Wijeysundera">Duminda Wijeysundera</name></author><author><name sortKey="Massey, Christine" sort="Massey, Christine" uniqKey="Massey C" first="Christine" last="Massey">Christine Massey</name></author><author><name sortKey="Kraeva, Natalia" sort="Kraeva, Natalia" uniqKey="Kraeva N" first="Natalia" last="Kraeva">Natalia Kraeva</name></author></analytic><series><title level="j">Anesthesia and analgesia</title><idno type="eISSN">1526-7598</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Anesthetics (adverse effects)</term><term>Caffeine (adverse effects)</term><term>Canada</term><term>Child</term><term>Child, Preschool</term><term>Dantrolene (adverse effects)</term><term>Dantrolene (therapeutic use)</term><term>Female</term><term>Fever (diagnosis)</term><term>Halothane (adverse effects)</term><term>Humans</term><term>Hypercapnia (diagnosis)</term><term>Incidence</term><term>Infant</term><term>Male</term><term>Malignant Hyperthermia (epidemiology)</term><term>Malignant Hyperthermia (etiology)</term><term>Middle Aged</term><term>Mutation</term><term>Registries</term><term>Retrospective Studies</term><term>Ryanodine Receptor Calcium Release Channel (genetics)</term><term>Succinylcholine (chemistry)</term><term>Tachycardia (diagnosis)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anesthésiques (effets indésirables)</term><term>Caféine (effets indésirables)</term><term>Canada</term><term>Canal de libération du calcium du récepteur à la ryanodine (génétique)</term><term>Dantrolène (effets indésirables)</term><term>Dantrolène (usage thérapeutique)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Enregistrements</term><term>Femelle</term><term>Fièvre (diagnostic)</term><term>Halothane (effets indésirables)</term><term>Humains</term><term>Hypercapnie (diagnostic)</term><term>Hyperthermie maligne (épidémiologie)</term><term>Hyperthermie maligne (étiologie)</term><term>Incidence</term><term>Jeune adulte</term><term>Mutation</term><term>Mâle</term><term>Nourrisson</term><term>Sujet âgé</term><term>Suxaméthonium ()</term><term>Tachycardie (diagnostic)</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anesthetics</term><term>Caffeine</term><term>Dantrolene</term><term>Halothane</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Succinylcholine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Ryanodine Receptor Calcium Release Channel</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dantrolene</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Fever</term><term>Hypercapnia</term><term>Tachycardia</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Fièvre</term><term>Hypercapnie</term><term>Tachycardie</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anesthésiques</term><term>Caféine</term><term>Dantrolène</term><term>Halothane</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Malignant Hyperthermia</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Malignant Hyperthermia</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Canal de libération du calcium du récepteur à la ryanodine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Dantrolène</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Hyperthermie maligne</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hyperthermie maligne</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Incidence</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Mutation</term><term>Registries</term><term>Retrospective Studies</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Canada</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Enregistrements</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Jeune adulte</term><term>Mutation</term><term>Mâle</term><term>Nourrisson</term><term>Sujet âgé</term><term>Suxaméthonium</term><term>Études rétrospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Between 1992 and 2011, 373 Canadian individuals with adverse anesthetic reaction were referred to the Malignant Hyperthermia Unit in Toronto, Ontario, Canada for malignant hyperthermia (MH) diagnostic testing. We analyzed the epidemiologic characteristics of the index adverse anesthetics for those probands who were confirmed to be MH susceptible.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Hu, Charles" sort="Hu, Charles" uniqKey="Hu C" first="Charles" last="Hu">Charles Hu</name><name sortKey="Kraeva, Natalia" sort="Kraeva, Natalia" uniqKey="Kraeva N" first="Natalia" last="Kraeva">Natalia Kraeva</name><name sortKey="Larach, Marilyn Green" sort="Larach, Marilyn Green" uniqKey="Larach M" first="Marilyn Green" last="Larach">Marilyn Green Larach</name><name sortKey="Massey, Christine" sort="Massey, Christine" uniqKey="Massey C" first="Christine" last="Massey">Christine Massey</name><name sortKey="Wijeysundera, Duminda" sort="Wijeysundera, Duminda" uniqKey="Wijeysundera D" first="Duminda" last="Wijeysundera">Duminda Wijeysundera</name></noCountry><country name="Canada"><noRegion><name sortKey="Riazi, Sheila" sort="Riazi, Sheila" uniqKey="Riazi S" first="Sheila" last="Riazi">Sheila Riazi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Canada/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000118 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd -nk 000118 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Canada
|étape= Analysis
|type= RBID
|clé= pubmed:23842196
|texte= Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/RBID.i -Sk "pubmed:23842196" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |